Cero Therapeutics announces FDA ODD granted to CER-1236

CERo Therapeutics (CERO) announces that the U.S. Food and Drug Administration, FDA, has granted CERo’s Orphan Drug Designation, ODD, for the company’s lead drug candidate CER-1236, for the treatment of acute myeloid leukemia, AML. CER-1236 is an innovative therapy that engineers a cancer patient’s own T cell therapeutics that deploy phagocytic mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells. Chris Ehrlich, CERo CEO, commented, “Orphan Drug Designation underscores the importance of developing new treatments for AML, and the potential for CER-1236 to provide a new and differentiated approach toward treatment. We believe that we are at the forefront of innovation in immuno-oncology and are grateful for the recognition from FDA. We look forward to providing updates on our trial in the near term.”